⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL

Published 15/04/2024, 09:14 pm
INMD
-

YOKNEAM, Israel, April 15, 2024 /PRNewswire/ -- InMode (NASDAQ:INMD) Ltd. (Nasdaq: INMD),  a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511.   Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe the patent. That litigation is ongoing.

InMode's Chief Technology Officer, Dr. Michael Kreindel, commented "The filing of a USPTO petition for Inter Partes review by a defendant accused of patent infringement is commonplace, and something that occurs in most important patent disputes.   BTL's petition did not come as a surprise to us, and we look forward to defending the validity of our patent before the USPTO."   Dr. Kreindel added "We also look forward to continuing our case against BTL in the California district court to protect the valuable technology that our patent covers.   We acquired this cutting edge technology from Viveve to complement our own developmental efforts, and when others like BTL use it we take vigorous action."  

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Forward-Looking Statements

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including, but not limited to, the 2024 revenue projection described above.  Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Company Contact:

Yair Malca

Chief Financial Officer

Phone: (949) 305-0108

Email: Yair.Malca@inmodemd.com

Investor Relations Contact:

Miri Segal

MS-IR LLC

Phone: (917) 607-8654

Email: ir@inmodemd.com

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.